Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06247540 Withdrawn - Richter Syndrome Clinical Trials

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: March 29, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.

NCT ID: NCT06104878 Withdrawn - Hodgkin Lymphoma Clinical Trials

A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Start date: December 31, 2023
Phase:
Study type: Observational

The main aim of this study conducted in Brazil is to understand if there is a difference in the length of time that Classical Hodgkin's Lymphoma (cHL) does not grow or spread further (also called progression free survival or PFS), and in the length of time that participants live with cHL if they are treated with Brentuximab Vedotin in combination with chemotherapy (A+AVD) or chemotherapy alone (ABVD). A+AVD includes Brentuximab Vedotin + Doxorubicin + Vinblastine + Dacarbazine; ABVD includes Doxorubicin + Bleomycin + Vinblastine + Dacarbazine. The study will be conducted by reviewing and collecting already existing medical records.

NCT ID: NCT05934097 Withdrawn - Clinical trials for Mantle Cell Lymphoma

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.

NCT ID: NCT05929716 Withdrawn - B-cell Lymphoma Clinical Trials

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Start date: September 30, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of the combination of magrolimab, rituximab, and radiation as bridging therapy in patients with relapsed or refractory LBCL who receive CAR T-Cell Therapy (CART).

NCT ID: NCT05867030 Withdrawn - Follicular Lymphoma Clinical Trials

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Start date: July 28, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

NCT ID: NCT05796271 Withdrawn - Lymphoma, B-Cell Clinical Trials

Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This study is an investigator-initiated, phase II, single arm, open label clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at moderate or high risk for poor outcome, defined as an NCCN-IPI score of 2 or higher. All subjects will receive investigational drug, and outcomes will be compared to historical controls.

NCT ID: NCT05711628 Withdrawn - Clinical trials for Refractory Classic Hodgkin Lymphoma

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Start date: August 10, 2023
Phase: Phase 3
Study type: Interventional

This phase III trial compares chemotherapy versus an immune checkpoint inhibitor drug called pembrolizumab plus chemotherapy in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or that does not respond to treatment (refractory). The usual approach for patients with classical Hodgkin lymphoma is treatment with standard chemotherapy, including drugs that are Food and Drug Administration (FDA)-approved. If this treatment puts a patient into remission, high dose chemotherapy and stem cell transplant may be used to increase the likelihood of a cure. Hodgkin lymphoma is capable of inhibiting the immune system from killing it. Pembrolizumab is a checkpoint inhibitor that may be able to stop this inhibition, allowing the immune system to attack the lymphoma.

NCT ID: NCT05613348 Withdrawn - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

CAR19T2
Start date: December 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.

NCT ID: NCT05604417 Withdrawn - Clinical trials for Refractory Follicular Lymphoma

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Start date: January 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.

NCT ID: NCT05513612 Withdrawn - Clinical trials for Acute Myeloid Leukemia (AML)

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Start date: August 1, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.